Research ArticleClinical Investigations
Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders and Wim J.G. Oyen
Journal of Nuclear Medicine February 2014, 55 (2) 242-247; DOI: https://doi.org/10.2967/jnumed.113.131110
Constantijn H.J. Muselaers
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
2Radboud university medical center, Department of Nuclear Medicine, Nijmegen, The Netherlands
Alexander B. Stillebroer
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
Ingrid M.E. Desar
3Radboud university medical center, Department of Medical Oncology, Nijmegen, The Netherlands; and
Marye J. Boers-Sonderen
3Radboud university medical center, Department of Medical Oncology, Nijmegen, The Netherlands; and
Carla M.L. van Herpen
3Radboud university medical center, Department of Medical Oncology, Nijmegen, The Netherlands; and
Mirjam C.A. de Weijert
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
Johan F. Langenhuijsen
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
Egbert Oosterwijk
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
William P.J. Leenders
4Radboud university medical center, Department of Pathology, Nijmegen, The Netherlands
Otto C. Boerman
2Radboud university medical center, Department of Nuclear Medicine, Nijmegen, The Netherlands
Peter F.A. Mulders
1Radboud university medical center, Department of Urology, Nijmegen, The Netherlands
Wim J.G. Oyen
2Radboud university medical center, Department of Nuclear Medicine, Nijmegen, The Netherlands
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 2
February 1, 2014
Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders, Wim J.G. Oyen
Journal of Nuclear Medicine Feb 2014, 55 (2) 242-247; DOI: 10.2967/jnumed.113.131110
Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders, Wim J.G. Oyen
Journal of Nuclear Medicine Feb 2014, 55 (2) 242-247; DOI: 10.2967/jnumed.113.131110
Jump to section
Related Articles
Cited By...
- Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
- Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers
- Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges